Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) EBT Margin (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed EBT Margin for 6 consecutive years, with 5.44% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin rose 810140.0% year-over-year to 5.44%, compared with a TTM value of 549.62% through Sep 2025, up 608325.0%, and an annual FY2024 reading of 4670.14%, up 868164.0% over the prior year.
  • EBT Margin was 5.44% for Q3 2025 at Ovid Therapeutics, up from 74.68% in the prior quarter.
  • Across five years, EBT Margin topped out at 5042.01% in Q2 2024 and bottomed at 107798.32% in Q3 2022.
  • Average EBT Margin over 5 years is 11662.35%, with a median of 929.45% recorded in 2025.
  • Peak annual rise in EBT Margin hit 9747447bps in 2023, while the deepest fall reached -1845214bps in 2023.
  • Year by year, EBT Margin stood at 84.7% in 2021, then plummeted by -106bps to 5.17% in 2022, then tumbled by -199561bps to 10323.85% in 2023, then fell by -18bps to 12175.0% in 2024, then skyrocketed by 100bps to 5.44% in 2025.
  • Business Quant data shows EBT Margin for OVID at 5.44% in Q3 2025, 74.68% in Q2 2025, and 4.58% in Q1 2025.